- Home
- GOSS vs TVRD Comparison
GOSS vs TVRD Comparison
Compare GOSS & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- TVRD
- Stock Information
- Founded
- GOSS 2015
- TVRD 2017
- Country
- GOSS United States
- TVRD United States
- Employees
- GOSS N/A
- TVRD N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- TVRD Health Care
- Exchange
- GOSS Nasdaq
- TVRD Nasdaq
- Market Cap
- GOSS 262.5M
- TVRD 246.5M
- IPO Year
- GOSS 2019
- TVRD N/A
- Fundamental
- Price
- GOSS $1.23
- TVRD $23.33
- Analyst Decision
- GOSS Strong Buy
- TVRD Strong Buy
- Analyst Count
- GOSS 4
- TVRD 3
- Target Price
- GOSS $7.75
- TVRD $60.67
- AVG Volume (30 Days)
- GOSS 2.6M
- TVRD 100.1K
- Earning Date
- GOSS 08-11-2025
- TVRD 08-21-2025
- Dividend Yield
- GOSS N/A
- TVRD N/A
- EPS Growth
- GOSS N/A
- TVRD N/A
- EPS
- GOSS N/A
- TVRD N/A
- Revenue
- GOSS $124,590,000.00
- TVRD N/A
- Revenue This Year
- GOSS N/A
- TVRD N/A
- Revenue Next Year
- GOSS $91.14
- TVRD N/A
- P/E Ratio
- GOSS N/A
- TVRD N/A
- Revenue Growth
- GOSS N/A
- TVRD N/A
- 52 Week Low
- GOSS $0.66
- TVRD $8.13
- 52 Week High
- GOSS $1.55
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- GOSS 54.09
- TVRD N/A
- Support Level
- GOSS $1.25
- TVRD N/A
- Resistance Level
- GOSS $1.44
- TVRD N/A
- Average True Range (ATR)
- GOSS 0.10
- TVRD 0.00
- MACD
- GOSS -0.00
- TVRD 0.00
- Stochastic Oscillator
- GOSS 41.67
- TVRD 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.